Exelixis
EXEL • NASDAQ
Exelixis is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Michael Morrissey, with a market cap of $10.8B.
CEOMichael Morrissey
Next Earnings
Upcoming earnings announcement for Exelixis
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.73
Revenue Estimate
$611.3M
Earnings History
Past 12 earnings reports for Exelixis
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 10, 2026 | Q4 2025 | $0.94Est: $0.76 | +23.7% | $598.7MEst: $594.5M | +0.7% |  10-K |
| Nov 4, 2025 | Q3 2025 | $0.78Est: $0.63 | +23.8% | $597.8MEst: $589.4M | +1.4% | 10-Q |
| Jul 28, 2025 | Q2 2025 | $0.75Est: $0.61 | +23.0% | $568.3MEst: $577.7M | -1.6% | 10-Q |
| May 13, 2025 | Q1 2025 | $0.62Est: $0.44 | +40.9% | $555.4MEst: $501.0M | +10.9% | 10-Q |
| Feb 11, 2025 | Q4 2024 | $0.55Est: $0.49 | +12.2% | $566.8MEst: $563.2M | +0.6% | 10-K |
| Oct 29, 2024 | Q3 2024 | $0.47Est: $0.35 | +34.3% | $539.5MEst: $490.0M | +10.1% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $0.84Est: $0.30 | +180.0% | $637.2MEst: $465.5M | +36.9% | 10-Q |
| Apr 30, 2024 | Q1 2024 | $0.17Est: $0.24 | -29.2% | $425.2MEst: $456.4M | -6.8% | 10-Q |
| Feb 6, 2024 | Q4 2023 | $0.33Est: $0.22 | +50.0% | $479.7MEst: $484.9M | -1.1% | 10-K |
| Nov 1, 2023 | Q3 2023 | $0.10Est: $0.15 | -33.3% | $471.9MEst: $472.2M | -0.1% | — |
| Aug 1, 2023 | Q2 2023 | $0.31Est: $0.22 | +40.9% | $469.8MEst: $450.1M | +4.4% | 10-Q |
| May 9, 2023 | Q1 2023 | $0.16Est: $0.15 | +6.7% | $408.8MEst: $424.1M | -3.6% | — |